ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company StrategyGlobeNewsWire • 04/13/22
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing SummitGlobeNewsWire • 04/04/22
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial ResultsGlobeNewsWire • 02/24/22
Will ProQR (PRQR) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/17/22
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10GlobeNewsWire • 02/11/22
Strength Seen in ProQR (PRQR): Can Its 7% Jump Turn into More Strength?Zacks Investment Research • 02/02/22
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of SepofarsenGlobeNewsWire • 01/04/22
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos CapitalGlobeNewsWire • 12/30/21